Home › Daiichi Sankyo and ArQule Announce Top-Line Results of Phase 2 Trial...
 

Keywords :   


Daiichi Sankyo and ArQule Announce Top-Line Results of Phase 2 Trial...

2013-01-12 04:25:40| Biotech - Topix.net

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced the top-line results of a randomized Phase 2 signal generation trial of tivantinib used in combination with irinotecan and cetuximab in patients with refractory or relapsed colorectal cancer .

Tags: results trial phase announce

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Atlantic Tropical Weather Outlook
05.10Tropical Storm Milton Update Statement
05.10Summary for Tropical Storm Milton (AT4/AL142024)
05.10Eastern North Pacific Tropical Weather Outlook
05.10Tropical Depression Fourteen Graphics
05.10Tropical Depression Fourteen Forecast Discussion Number 1
05.10Tropical Depression Fourteen Wind Speed Probabilities Number 1
05.10Tropical Depression Fourteen Public Advisory Number 1
More »